miR-155在非小细胞肺癌患者血清中的表达及其临床意义  

Expression and clinical value of miR-155 in patients with non-small cell lung cancer

作　　者：杨健[1] 张秀伟[1] 文昱婷[1] 俞军[2] 

机构地区：[1]南京江宁医院呼吸科,江苏省南京市211100 [2]江苏省肿瘤医院科研科,江苏省南京市210009

出　　处：《实用老年医学》2012年第6期459-461,共3页Practical Geriatrics

摘　　要：目的探讨非小细胞肺癌(NSCLC)患者血清微小RNA-155(microRNA-155,miR-155)水平及其临床意义。方法采用荧光实时定量逆转录聚合酶链反应法检测58例NSCLC患者和42例健康体检者血清miR-155的表达,并分析其与临床、病理资料的相关性。结果 NSCLC患者血清miR-155的表达水平明显升高,而且其表达与组织分化、临床分期、淋巴结转移显著相关(P<0.05),而在不同年龄、性别和病理类型患者间差异无统计学意义(P>0.05)。结论 NSCLC患者血清miR-155水平与肿瘤分型、临床分期和术后复发显著相关,可以作为NSCLC诊断和预后判断的肿瘤标志物。Objective To explore the expression of miR-155 in non-small cell lung cancer（NSCLC）and its clinical value. Methods The levels of miR-155 in serums was detected by real-time quantitative reverse transcription polymerase chain reaction（qRT-PCR） in 58 patients with NSCLC and 42 normal persons. Results The expression of miR-155 in NSCLC was increased, furthermore, it was related to histo-differentiation, clinical stage and lymph node metastasis （P0.05）.No correlation was found in patients with different age,sex and pathological type （P0.05）. Conclusions miR-155 might play an important role in NSCLC. It could be a prognostic marker for NSCLC.

关 键 词：非小细胞肺癌 微小RNA-155 荧光实时定量PCR 

分 类 号：R734.2[医药卫生—肿瘤] R446.7[医药卫生—临床医学]